Your browser doesn't support javascript.
loading
Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network.
Stidham, Joseph; Feingold, Brian; Almond, Christopher S; Burstein, Danielle S; Krack, Paige; Price, Jack F; Schumacher, Kurt R; Spinner, Joseph A; Rosenthal, David N; Lorts, Angela; Godown, Justin.
Afiliação
  • Stidham J; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Feingold B; Division of Pediatric Cardiology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Almond CS; Department of Pediatrics (Pediatric Cardiology), Stanford University, Palo Alto, CA, USA.
  • Burstein DS; Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Krack P; Division of Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, USA.
  • Price JF; Division of Pediatric Cardiology, Texas Children's Hospital, Houston, TX, USA.
  • Schumacher KR; Division of Pediatric Cardiology, University of Michigan, Ann Arbor, MI, USA.
  • Spinner JA; Division of Pediatric Cardiology, Texas Children's Hospital, Houston, TX, USA.
  • Rosenthal DN; Department of Pediatrics (Pediatric Cardiology), Stanford University, Palo Alto, CA, USA.
  • Lorts A; Division of Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, USA.
  • Godown J; Division of Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA. Justin.Godown@vumc.org.
Pediatr Cardiol ; 42(2): 315-323, 2021 Feb.
Article em En | MEDLINE | ID: mdl-33044586
ABSTRACT
Heart failure metrics specific to the pediatric population are required to successfully implement quality improvement initiatives in children with heart failure. Medication use at the time of discharge following admission for decompensated heart failure has been identified as a potential quality metric in this population. This study aimed to report medication use at discharge in the current era for children admitted with acute decompensated heart failure. All patients < 21 years of age with an index admission (1/1/2011-12/31/2019) for acute heart failure and a coexisting diagnosis of cardiomyopathy were identified from the Pediatric Health Information System. Medication use patterns were described and compared across age groups and centers. A total of 2288 patients were identified for inclusion. An angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker (ACEi/ARB) was prescribed in 1479 (64.6%), beta blocker in 1132 (49.5%), and mineralocorticoid receptor antagonist (MRA) in 864 (37.8%) patients at discharge. The use of ACEi/ARB at discharge has decreased over time (64.6% vs. 69.6%, p = 0.001) and the use of beta blockers has increased (49.5% vs. 36.8%, p < 0.001) compared to a historical cohort (2001-2010). There is considerable variability in medication use across centers with an overall increase in beta blocker and decrease in ACEi/ARB use over time. Collaborative efforts are needed to standardize care and define quality metrics to identify best practices in the management of pediatric heart failure.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Antagonistas Adrenérgicos beta / Antagonistas de Receptores de Mineralocorticoides / Antagonistas de Receptores de Angiotensina / Insuficiência Cardíaca Tipo de estudo: Guideline / Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Antagonistas Adrenérgicos beta / Antagonistas de Receptores de Mineralocorticoides / Antagonistas de Receptores de Angiotensina / Insuficiência Cardíaca Tipo de estudo: Guideline / Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article